FVIII concentrate

ApprovedSmall molecule

TThe University of Texas Health Science Center, Houston

FVIII concentrate is one of 49 small molecule programs targeting Hemophilia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemophiliaActive, not recruiting

SynovitisActive, not recruiting

HemophiliaPreclinical

Active, not recruiting

SynovitisApproved

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Hemophilia

#DrugCompanyPhaseTrials

Videx

Bristol-Myers Squibb

Approved

1 2

Crixivan

Merck & Co.

Approved

1 3

Hivid

CConrado Roberto Hoffmann Filho

Approved

1 4

Zerit

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 5

Epivir

GGlaxo Dba Glaxosmithkline

Approved

1 6

Cyklokapron

Daklinza

1 8

Recombinant Factor VIII

Bayer

Approved

1 9

Antithrombin Concentrate (ATIIIC)

Sanofi

Approved

3 10

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Synovitis1 trial

Intensive Replacement Treatment in Haemophilia Patients With Synovitis

Completed·FFederico II University·Phase 4·NCT04784988·64 enrolled

Hemophilia1 trial

Hemophilia Inhibitor Previously Untreated Patient Study

Completed·TThe University of Texas Health Science Center, Houston··NCT01652027·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FVIII concentrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FVIII concentrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FVIII concentrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe University of Texas Health Science Center, Houston

FVIII concentrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Synovitis1 trial

Hemophilia1 trial

References

Drug Info

Quick Facts

Related News